Literature DB >> 10508318

Cerebral (1)H MRS alterations in recreational 3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy") users.

L Chang1, T Ernst, C S Grob, R E Poland.   

Abstract

3,4-methylenedioxymethamphetamine (MDMA) is an illicit drug that has been associated with serotonergic axonal degeneration in animals. This study evaluates neurochemical abnormalities in recreational MDMA users. Twenty-two MDMA users and 37 normal subjects were evaluated with magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) in the mid-frontal, mid-occipital, and parietal brain regions. (1)H MRS showed normal N-acetyl (NA) compounds in all brain regions. The myo-inositol (MI) concentration (+16.3%, P = 0.04) and the MI to creatine (CR) ratio (+14.1%, P = 0. 01) were increased in the parietal white matter of MDMA users. The cumulative lifetime MDMA dose showed significant effects on [MI] in the parietal white matter and the occipital cortex. The normal NA concentration suggests a lack of significant neuronal injury in recreational MDMA users. However, the usage-related increase in MI suggests that exposure to MDMA, even at recreational doses, may cause increased glial content. J. Magn. Reson. Imaging 1999;10:521-526. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508318     DOI: 10.1002/(sici)1522-2586(199910)10:4<521::aid-jmri4>3.0.co;2-9

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  18 in total

1.  The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance.

Authors:  Maartje M L De Win; Gerry Jager; Hylke K E Vervaeke; Thelma Schilt; Liesbeth Reneman; Jan Booij; Frank C Verhulst; Gerard J Den Heeten; Nick F Ramsey; Dirk J Korf; Wim Van den Brink
Journal:  Int J Methods Psychiatr Res       Date:  2005       Impact factor: 4.035

Review 2.  Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction.

Authors:  Stephanie C Licata; Perry F Renshaw
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 3.  Imaging Biomarkers of the Neuroimmune System among Substance Use Disorders: A Systematic Review.

Authors:  Eric A Woodcock; Ansel T Hillmer; Graeme F Mason; Kelly P Cosgrove
Journal:  Mol Neuropsychiatry       Date:  2019-05-09

Review 4.  Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain.

Authors:  Linda Chang; Sody M Munsaka; Stephanie Kraft-Terry; Thomas Ernst
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-12       Impact factor: 4.147

5.  Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphetamine (Ecstasy) users: preliminary results.

Authors:  Liesbeth Reneman; Charles B L M Majoie; Herman Flick; Gerard J den Heeten
Journal:  AJNR Am J Neuroradiol       Date:  2002-02       Impact factor: 3.825

Review 6.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

7.  Occipital cortical proton MRS at 4 Tesla in human moderate MDMA polydrug users.

Authors:  Ronald L Cowan; Nicolas R Bolo; Mary Dietrich; Erica Haga; Scott E Lukas; Perry F Renshaw
Journal:  Psychiatry Res       Date:  2007-06-18       Impact factor: 3.222

8.  Neuroimaging in human MDMA (Ecstasy) users.

Authors:  Ronald L Cowan; Deanne M Roberts; James M Joers
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

9.  The Role of Glial Cells in Drug Abuse.

Authors:  Jose Javier Miguel-Hidalgo
Journal:  Curr Drug Abuse Rev       Date:  2009

Review 10.  The Utility of Magnetic Resonance Spectroscopy for Understanding Substance Use Disorders: A Systematic Review of the Literature.

Authors:  Tracy Hellem; Xianfeng Shi; Gwen Latendresse; Perry F Renshaw
Journal:  J Am Psychiatr Nurses Assoc       Date:  2015 Jul-Aug       Impact factor: 2.385

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.